A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NCT07548060 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IV
EGFR Gene Mutation

Interventions

DRUG: sacituzumab tirumotecan

Sponsor

Tianjin Medical University Cancer Institute and Hospital